162 249

Cited 3 times in

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

DC Field Value Language
dc.contributor.author박지혜-
dc.contributor.author천재희-
dc.date.accessioned2022-12-22T03:44:11Z-
dc.date.available2022-12-22T03:44:11Z-
dc.date.issued2022-09-
dc.identifier.issn1226-3303-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191961-
dc.description.abstractThe incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospitalization, emergency room visits, or surgery may be required, resulting in a socioeconomic burden. Great advances have been made in the development of new therapeutic options for IBD to achieve induction and maintenance remission. Nevertheless, conventional therapy is still the mainstay in the treatment of IBD. This review article provides an update on recent advances in conventional therapies, including 5-aminosalicylates, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents to treat IBD.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association of Internal Medicine-
dc.relation.isPartOfKOREAN JOURNAL OF INTERNAL MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdrenal Cortex Hormones / adverse effects-
dc.subject.MESHHumans-
dc.subject.MESHImmunologic Factors / adverse effects-
dc.subject.MESHInflammatory Bowel Diseases* / drug therapy-
dc.subject.MESHMesalamine* / adverse effects-
dc.subject.MESHTumor Necrosis Factor Inhibitors-
dc.subject.MESHTumor Necrosis Factor-alpha-
dc.titleUpdates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJihye Park-
dc.contributor.googleauthorJae Hee Cheon-
dc.identifier.doi10.3904/kjim.2022.132-
dc.contributor.localIdA04575-
dc.contributor.localIdA04030-
dc.relation.journalcodeJ02883-
dc.identifier.eissn2005-6648-
dc.identifier.pmid35882566-
dc.subject.keywordAdrenal cortex hormones-
dc.subject.keywordAnti-TNF agents-
dc.subject.keywordImmunologic factors-
dc.subject.keywordInflammatory bowel diseases-
dc.subject.keywordMesalamine-
dc.contributor.alternativeNamePark, Ji Hye-
dc.contributor.affiliatedAuthor박지혜-
dc.contributor.affiliatedAuthor천재희-
dc.citation.volume37-
dc.citation.number5-
dc.citation.startPage895-
dc.citation.endPage905-
dc.identifier.bibliographicCitationKOREAN JOURNAL OF INTERNAL MEDICINE, Vol.37(5) : 895-905, 2022-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.